Shank family proteins (Shank1, Shank2, and Shank3) are synaptic scaffolding proteins that organize an extensive protein complex at the postsynaptic density (PSD) of excitatory glutamatergic synapses. Recent human genetic studies indicate that SHANK family genes (SHANK1, SHANK2, and SHANK3) are causative genes for idiopathic autism spectrum disorders (ASD). Neurobiological studies of Shank mutations in mice support a general hypothesis of synaptic dysfunction in the pathophysiology of ASD. However, the molecular diversity of SHANK family gene products, as well as the heterogeneity in human and mouse phenotypes, pose challenges to modeling human SHANK mutations. Here, we review the molecular genetics of SHANK mutations in human ASD and discuss recent findings where such mutations have been modeled in mice. Conserved features of synaptic dysfunction and corresponding behaviors in Shank mouse mutants may help dissect the pathophysiology of ASD, but also highlight divergent phenotypes that arise from different mutations in the same gene.
Introduction
In recent years, tremendous progress has been made in recognizing and diagnosing autism, a condition that was first described by Kanner and Asperger nearly 70 years ago (Asperger, 1944; Kanner, 1943; Volkmar et al., 2009) . Clinically, autistic phenotypes are present in a group of heterogeneous conditions, termed autism spectrum disorders (ASD) (Lord et al., 2000a) . Genetic risk contributes significantly to idiopathic ASD, but the specific genetic alterations remain elusive in the majority of cases (Abrahams and Geschwind, 2008; Folstein and Rosen-Sheidley, 2001; State, 2010b) . Remarkably little is known about the underlying pathophysiology or neurological basis of ASD (Amaral et al., 2008; Courchesne et al., 2007; Geschwind and Levitt, 2007; Rubenstein, 2010; Zoghbi, 2003) . The development of animal models is an important step in bridging the human genetics of ASD to circuit-based deficits underlying the clinical presentation, and ultimately to discovering, designing, and deploying effective therapeutic strategies.
SHANK/ProSAP family proteins (SHANK1, SHANK2, SHANK3) have emerged as promising candidates for modeling ASD in mice due to strong genetic evidence showing molecular defects of SHANK in patients with ASD (Berkel et al., 2010 (Berkel et al., , 2012 Durand et al., 2007; Gauthier et al., 2010; Marshall et al., 2008; Pinto et al., 2010; Sato et al., 2012) . Mutations of SHANK3 were the first (Durand et al., 2007) and remain the best characterized SHANK mutations in human ASD (Boccuto et al., 2013; Moessner et al., 2007) . Recently, mutations in SHANK1 and SHANK2 have also been associated with ASD (Berkel et al., 2010 (Berkel et al., , 2012 Sato et al., 2012) , supporting a general function for this gene family in common molecular pathways associated with ASD. Shank family proteins are scaffolding proteins that organize a cytoskeleton-associated signaling complex at the postsynaptic density (PSD) of nearly all excitatory glutamatergic synapses in the mammalian brain (Grabrucker et al., 2011b; Gundelfinger et al., 2006; Kreienkamp, 2008; Sheng and Kim, 2000) . The genetic association of ASD with SHANK family genes provided an immediate link between synaptic dysfunction and the pathophysiology of ASD. Shank1 mutant mice were first reported in 2008 (Hung et al., 2008) . Recently, two Shank2 (Schmeisser et al., 2012; Won et al., 2012) and five Shank3 mutant mice have been reported (Bozdagi et al., 2010; Peç a et al., 2011; Schmeisser et al., 2012; Wang et al., 2011) . Analysis of these mutant mice has yielded a wealth of new information and raised numerous questions. Here, we compare and contrast the various Shank mouse models with a focus on Shank3, discuss the potential relevance to human ASD, and highlight key challenges and opportunities in studying the role of SHANK genes in ASD.
Genetic Linkage of SHANK Genes to Autism Spectrum Disorders
In humans, SHANK3 is one of the best characterized genes implicated in ASD. SHANK3 maps to the critical region of 22q13.3 deletion syndrome (Phelan-McDermid syndrome, PMS) ( Figure 1A ; Wilson et al., 2003) . The key clinical features associated with PMS are global developmental delay, hypotonia, absent or severely delayed language, autistic behaviors, and intellectual disability (Phelan, 2007) . Atypical bipolar disorder has also been associated with 22q13.3 deletions in recent case reports (Denayer et al., 2012; Verhoeven et al., 2012 Verhoeven et al., , 2013 . The size of the deletions in PMS is extremely variable (0.1-10 Mb) (Dhar et al., 2010; Wilson et al., 2003) , but deletions of SHANK3 have been reported in all cases except in one report of two children who have deletions proximal to SHANK3 (Wilson et al., 2008) , suggesting that other genes in 22q13.3 may also be important for brain function. Much smaller deletions specific to SHANK3 or balanced translocations within the SHANK3 gene have been reported in patients with neurobehavioral features indistinguishable from patients with large deletions including SHANK3 (Anderlid et al., 2002; Bonaglia et al., 2006; Wong et al., 1997) . These observations have led to the conclusion that haploinsufficiency of SHANK3 is a major contributor to the neurobehavioral features in 22q13.3 deletion patients. Subsequently, point mutations and microdeletions of SHANK3 have been identified in idiopathic ASD cases (Boccuto et al., 2013; Dhar et al., 2010; Durand et al., 2007; Gauthier et al., 2010; Gong et al., 2012; Marshall et al., 2008; Moessner et al., 2007; Waga et al., 2011) . In all, six types of molecular defects have been identified in SHANK3 in more than 1000 human patients. These include (1) cytogenetically visible terminal deletion of 22q13.3 or ring chromosome of 22 (Jeffries et al., 2005; Wilson et al., 2003) , (2) a microdeletion detected by array-based methods (Boccuto et al., 2013; Dhar et al., 2010) , (3) microduplication (Okamoto et al., 2007) , (4) translocations with breakpoints within the SHANK3 gene (Bonaglia et al., 2006) , (5) small intragenic deletions (Bonaglia et al., 2011) , and (6) point mutations (Boccuto et al., 2013; Durand et al., 2007; Moessner et al., 2007) .
De novo sequence changes in SHANK3 including missense, frame shift, and splice site mutations have been reported in ASD patients (Boccuto et al., 2013; Durand et al., 2007; Gauthier et al., 2010; Gauthier et al., 2009; Gong et al., 2012; Hamdan et al., 2011; Moessner et al., 2007; Schaaf et al., 2011; Waga et al., 2011) . The positions of these point mutations that are likely pathological are depicted in Figure 1A , and the major clinical features extracted from case reports are summarized in Table 1 . Point mutations affecting the splice acceptor site in intron 5 (Hamdan et al., 2011) and splice donor site of intron 19 (Gauthier et al., 2009) , as well as a one base pair insertional mutation in exon 21 causing a frame shift (p.A1227fs) (Durand et al., 2007) , were found in children with ASD and severe speech delay. The p.A447fs mutation was found in a child with atypical autism disorder and speech delay. This mutation was inherited from his father who also exhibits learning disability and attention deficit hyperactivity disorder (Boccuto et al., 2013) . In contrast, a splice mutation of c.1820-4G > A is associated with a child with mild ASD (Asperger syndrome) (Boccuto et al., 2013) . Intellectual disability was mild in the patient with the intron 5 splicing mutation (Hamdan et al., 2011) , severe in the patient with the p.A1227fs exon 21 mutation (Durand et al., 2007) , and was not described in the patient with the intron 19 splice mutation (Gauthier et al., 2009 ). The p.E1331fs mutation, which is in the last coding exon close to stop codon, was found in children with pervasive developmental disorder not otherwise specified (PDD-NOS) and severe intellectual disability (Boccuto et al., 2013) . Several small intragenic or interstitial deletions have also been reported (Bonaglia et al., 2011) . Intragenic deletions of exons 1-9 or exons 1-17 of SHANK3 have been found in patients exhibiting severe language delay and significant intellectual disability, but a formal evaluation for ASD was not performed in these two cases (Bonaglia et al., 2011) . Together, these data strongly support a conclusion that molecular defects of SHANK3 can cause ASD but with variable presentations. However, the frequency of putatively pathological mutations in SHANK3 appears to be rare in ASD (<0.75%) (Moessner et al., 2007) , and the degree to which SHANK3 mutations contribute to the population attributable risk of ASD is small (Betancur, 2011; Buxbaum, 2009; State, 2010b) . Many missense mutations have been identified in SHANK3 (Gauthier et al., 2009; Moessner et al., 2007; Schaaf et al., 2011) , but their clinical relevance has not been determined. Although the number of cases with point mutations that are clearly pathological in nature is still small, the clinical features from these cases reports suggest a genotype-phenotype correlation related to the autism diagnosis. Interestingly, point mutations, including a nonsense mutation in exon 21 (p.R1117X) of SHANK3 have been reported in families with schizophrenia and mild intellectual disability (Gauthier et al., 2010) . This observation is consistent with recent reports that similar copy number variants (CNVs) are found across many genomic loci in both ASD and schizophrenia (Cook and Scherer, 2008; Gejman et al., 2011; Moreno-De-Luca et al., 2010; Sanders et al., 2011) . Microduplications of SHANK3 have also been reported in children with developmental delay and dysmorphic features (Okamoto et al., 2007) , suggesting that SHANK3 gene dosage affects brain function.
More recently, point mutations of SHANK2 and microdeletions of SHANK1 and SHANK2 have been found in patients with ASD and intellectual disability (Figures 1B and 1C; Berkel et al., 2010; Leblond et al., 2012; O'Roak et al., 2012; Pinto et al., 2010; Sato et al., 2012) . Compared to SHANK3, the number of cases with SHANK2 mutations is small but convincing. All microdeletions found in ASD are intragenic deletions that disrupt the SHANK2 protein. A nonsense mutation in SHANK2 exon 24 encoding the proline-rich homer-binding domain has also been found in an ASD proband ( Figure 1B ; Berkel et al., 2010) . Mutations of SHANK3 at similar location were also found in ASD (Boccuto et al., 2013; Durand et al., 2007) . In the case of SHANK1, microdeletions including SHANK1 and two other adjacent genes were reported in five ASD individuals in two families with mild ASD ( Figure 1C ). Pathological point mutations have not yet been reported in ASD (Sato et al., 2012) .
To date, correlation between genotype and phenotype has been described in patients with 22q13.3 deletions including SHANK3 (Sarasua et al., 2011) . In most reports, clinical features were described by self-reporting or extracted from existing medical records. A summary of the molecular and clinical finding related to SHANK3 variants is provided in Table 1 based on the available data from individual reports in the literature (Boccuto et al., 2013; Bonaglia et al., 2011; Dhar et al., 2010; Gauthier et al., 2009 Gauthier et al., , 2010 Moessner et al., 2007; Philippe et al., 2008; Sarasua et al., 2011; Waga et al., 2011; Wilson et al., 2003) . Importantly, the quality of clinical data varies and is often incomplete in these reports and thus direct comparisons should be made with caution. Diagnostic evaluations for ASD were not conducted in the majority of cases or were carried out using different evaluation protocols. Because the clinical data are not complete in most cases, it is difficult to draw firm conclusions about the relationship between specific SHANK3 variants and clinical features related to ASD. This challenge is best illustrated in three cases with very similar mutations (p.A1227fs, p.E1311fs, and p.R1117X) in exon 21 encoding the proline-rich Homer binding site of SHANK3 ( Figure 1A ). Mutations p.A1227fs and p.E1331fs were found in patients with ASD or PDD-NOS, severe language delay, and significant intellectual disability (Boccuto et al., 2013; Durand et al., 2007) , while p.R1117X was found in patients with schizophrenia and mild intellectual disability (Gauthier et al., 2010) . Similarly, in other cases with almost identical small microdeletions (<100 kb) including SHANK3, 
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Review neurobehavioral phenotypes were quite variable (Boccuto et al., 2013; Bonaglia et al., 2011; Dhar et al., 2010) . One hypothesis to explain these differences is the presence of a genetic or epigenetic variant in the other allele of SHANK3, or haploinsufficiency and positional effects of deletions on other genes known to cause autosomal-recessive neurological disorders in the 22q13.3 region. For example, genes implicated in metachromatic leukodystrophy (ARSA), congenital disorders of glycosylation (ALG12), and spinocerebellar ataxia type 10 (ATXN10) are mapped within the 22q13.3 region. In addition, mutations or allelic variation in as-yet-unidentified genes that function as epistatic modifiers for SHANK3 could influence the phenotypes associated with SHANK3 defects.
In the cases of SHANK1 and SHANK2 mutations associated with ASD, no studies relating genotype and phenotype have been reported. The penetrance of SHANK2 mutations in ASD is not complete in some cases . This observation has led to the proposal of a multiple hit model to explain the clinical relevance of SHANK2 mutations. Because the number of ASD cases with two genetic hits including SHANK2 is small, the validity of the model remains to be tested in additional patient cohorts or by functional studies. Interestingly, microdeletion of SHANK1 is only penetrant in males with mild ASD in families studied (Sato et al., 2012) . The molecular basis for gender-specific penetrance related to SHANK1 mutations is not immediately clear but may provide an opportunity to investigate mechanisms underlying higher male gender-specific risk in ASD.
Deletions involving entire SHANK family genes in ASD predict that haploinsufficiency is the primary mechanism underlying ASD pathogenesis (Wilson et al., 2003) . By comparison, for point mutations such as missense mutation and small intragenic deletions identified in SHANK2 and SHANK3, the pathogenic mechanism is less clear (Bonaglia et al., 2011; Durand et al., 2012; Moessner et al., 2007) . The possibility of gain-of-function or dominant-negative effects in addition to loss-of-function should be considered if mutated mRNA transcripts produce stable mutated or truncated proteins. Different SHANK mutations may thus act through different mechanisms to alter protein-protein interactions at the PSD and cause synaptic dysfunction that may underlie clinical presentations of disorder. However, to date, we have little information on the molecular mechanisms by which more subtle mutations in SHANK3 alter protein function at synapses (Durand et al., 2007 (Durand et al., , 2012 .
SHANK Encodes a Multidomain Scaffolding Protein Present at Glutamatergic Synapses
Shank/ProSAP family members including Shank3 have five conserved protein domains-an ankyrin repeat domain (ANK), Src homology 3 (SH3) domain, a PSD-95/Discs large/ZO-1 (PDZ) domain, a proline-rich region containing homer-and cortactin-binding sites (Pro), and a sterile alpha motif (SAM) domain (Figure 2A ). Shanks are scaffolding proteins that interact with many synaptic proteins in the PSD (Ehlers, 1999; Gundelfinger et al., 2006; Kreienkamp, 2008; Sheng and Kim, 2000) . More than 30 synaptic proteins have been reported to interact with Shank family proteins ( Figure 2 and Table 2 ). Due to the similarity of protein domains among Shank family proteins, in vitro binding experiments have shown a significant overlap in protein-protein interactions involving Shank1-3. Shank3-interacting proteins include receptors, ion channels, cytoskeletal proteins, scaffolding proteins, enzymes, and signaling molecules (Grabrucker et al., 2011b; Kreienkamp, 2008) . The large protein complex organized by Shanks performs a variety of functions at the postsynaptic membrane including actin-based cytoskeletal remodeling, synapse formation, AMPA receptor endocytosis, and regulation of synaptic transmission and plasticity (Table 2) . Whether all these protein-protein interactions occur in vivo are unknown and the precise function for these interactions remains to be fully elucidated.
Concentrated at glutamatergic synapses, Shanks interact directly or indirectly with all major types of glutamate receptors-NMDA receptors, AMPA receptors, and mGluRs-via different domains (Ehlers, 1999; Naisbitt et al., 1999; Tu et al., 1999; Uchino et al., 2006; Verpelli et al., 2011) . When overexpressed in cultured neurons from mice, Shanks recruit GluA1 AMPA receptors and increases the formation of new synapses (Roussignol et al., 2005) . Expression of Shank3 with deletions of various domains in cultured mouse neurons has demonstrated distinct roles for each domain in dendritic spine development (Roussignol et al., 2005) . For example, mutation of the PDZ domain of Shank3 results in a reduction in dendritic spine formation while mutation of ANK-SH3 domains leads to spines with normal length but reduced spine head area. In contrast, mutation in the cortactin binding site results in longer spines with reduced spine head area (Roussignol et al., 2005) .
At present, it is unclear how the interactions of Shanks with various glutamate receptor subtypes are coordinated and regulated at a given synapse. In cultured rat neurons, knock-down of newly identified exon. The positions of six identified promoters are indicated as black arrows. The exons in red are alternatively spliced. The positions of point mutations are indicated as blue arrows and the nature of point mutations are as described above the arrow. c.601-1G > A splicing mutation in intron 5 (Hamdan et al., 2011) , p.Q312R in exon 8 (Moessner et al., 2007) , p.G440_P446 del and p.A447fs in exon 11 (Boccuto et al., 2013; Waga et al., 2011) , c.1820-4 G > A splicing mutation in intron 15 (Boccuto et al., 2013) , p.R656H in exon 16 (Waga et al., 2011) , c.2265+1 delG splicing mutation in intron 19 (Gauthier et al., 2009) , and p.R1117X, p.A1227fs, p.E1311fs in exon 21 (Boccuto et al., 2013; Durand et al., 2007; Gauthier et al., 2010) . Protein domains are shown and aligned to corresponding exons (ANK, ankyrin repeat domain; SH3, Src homology 3 domain; PDZ, PSD-95/Discs large/ZO-1 domain; Pro, a proline-rich region containing homer-and cortactin-binding sites; SAM, sterile alpha motif domain). CpG islands are sites of differential methylation and are indicated by green bars. (B) SHANK2 gene structure, protein domains, isoforms, microdeletions and mutations in ASD. Exons in red are alternatively spliced exons. Microdeletions found in ASD are intragenic and within the SHANK2 genomic region. Point mutations found in ASD are indicated as blue arrows and the nature of mutations are described above the arrow. Three identifiable promoters corresponding to SHANK2E, 2A, 2B are indicated as black arrow. Two alternative stop codons (TAA) are indicated as yellow arrows. (C) SHANK1 gene structure, protein domains, isoforms, and microdeletions in ASD. Two small deletions including SHANK1 and two other genes are shown. No pathological point mutations in SHANK1 have been reported in ASD. The positions for two promoters are shown (Lim et al., 1999) . The alternative splicing and isoforms have not been fully characterized. In (A)-(C), genomic distance and exons are not drawn to scale. Shank3 selectively reduces synaptic mGluR5 receptor and impairs mGluR5-dependent signaling and plasticity (Verpelli et al., 2011) . Whether similar deficits are present in vivo is not yet clear, although excessive mGluR5 signaling has been implicated in fragile X syndrome (Krueger and Bear, 2011) , which has clinical overlap with 22q13.3 deletions (Phelan, 2008) . Among the various Shank binding proteins, Homer family members have been shown to regulate diverse synaptic functions (Hayashi et al., 2009; Sala et al., 2001; Tu et al., 1999) . Homer1 and Shank1 form a mesh-like matrix that is thought to function as an organizing lattice for PSD proteins (Hayashi et al., 2009) . Shank3 shares very similar protein domain structure to Shank1, suggesting that Shank3 participates in a similar protein network with Homer1. As with interactions involving glutamate receptors, it is not yet known how the multitude of Shank interactions with other scaffolding and signaling proteins at a given synapse are coordinated and regulated. Shank3 shares a similar protein domain structure but has a different expression pattern and subcellular localization than Shank1 and Shank2 (Bö ckers et al., 2004; Peç a et al., 2011; Tao-Cheng et al., 2010) . Shank3 forms multimers via its C-terminal SAM domain (Boeckers et al., 2005; Hayashi et al., 2009; Naisbitt et al., 1999) as well as its PDZ domain (IskenderianEpps and Imperiali, 2010) . The SAM domain of Shank3 has a Zn 2+ binding site that is important for Shank3 protein folding at the PSD as well as for synaptogenesis and synapse maturation in vitro Grabrucker et al., 2011a) . Biochemically, Shank family proteins are ubiquitinated in an activity-dependent manner in neurons (Ehlers, 2003) . The exact biochemical mechanism responsible the ubiquitination of Shank family protein remains to be determined. Many interesting questions related to the molecular function of Shank3 await further investigation. Does Shank3 interact with different proteins in a synapse-specific manner? Is the interaction of Shank3 with synaptic proteins regulated by activity? How do these interactions and post-translational modifications contribute to the synaptic defects in human ASD and intellectual disability associated with the SHANK3 defects? Because point mutations and microdeletions in similar domains of SHANK1 and SHANK2 have been reported in ASD (Berkel et al., 2010; Pinto et al., 2010; Sato et al., 2012) , an interesting question is do various SHANK mutations cause ASD by disrupting similar mechanisms at the synapse (State, 2010a)?
Molecular Diversity of SHANK Gene Products SHANK genes display a complex transcriptional regulation with multiple intragenic promoters and extensive alternatively spliced exons both in humans and mice Lim et al., 1999; Maunakea et al., 2010; McWilliams et al., 2004; Redecker et al., 2006; Wang et al., 2011; Wilson et al., 2003) . Transcripts of SHANK3 are the best characterized among the three family members in human and mice (Durand et al., 2007; Maunakea et al., 2010; Wang et al., 2011) . The alternatively spliced exons of Shank3 encode the SH3, proline-rich, and SAM domains ( Figure 1A ). Combinations of multiple intragenic promoters and alterative splicing result in an extensive array of mRNA and deduced protein isoforms. The exact number of protein isoforms has not been determined, but selected mRNA isoforms analyzed in silico indicate that each Shank3 isoform (Shank3a-f) has a unique combination of different protein domains as illustrated in Figure 2B . For example, Shank3e and Shank3f mRNAs lack exons encoding the PDZ domain that is responsible for the interaction with NMDA and AMPA receptors . Shank3b lacks the proline-rich and SAM domains that are critical for Homer binding and multimerization . Because each protein domain mediates a unique complement of protein-protein interactions (Hayashi et al., 2009; Roussignol et al., 2005) , it is likely that each Shank3 isoform has a distinct set of functions. An important area for future research will be to determine the function for each isoform in vivo and its relevance to synaptic and behavioral phenotypes. The diversity of SHANK3 isoforms may contribute to synaptic signaling and postsynaptic protein composition. In addition, since Shank3 mRNA has been found in dendrites (Bö ckers et al., 2004) , the specific Shank3 mRNAs targeted to dendrites or perhaps individual synapses may also be isoform specific.
The complexity of SHANK3 transcript structure indicates that point mutations, translocations, and intragenic deletions of SHANK3 found in ASD patients are isoform-specific. For example, the intron 5 splicing mutations in the exon encoding the ANK domain is only predicted to affect two long isoforms The information in the table is extracted from following reports: Boccuto et al., 2013; Bonaglia et al., 2011; Dhar et al., 2010; Durand et al., 2007; Gauthier et al., 2009 Gauthier et al., , 2010 Moessner et al., 2007; Phelan, 2007; Sarasua et al., 2011; Waga et al., 2011; Wilson et al., 2003; Wong et al., 1997) . ACR, Acrosin, a sperm specific proteinase which has no known function in brain; ABC, autism behavioral checklist; ADHD, attention deficit-hyperactivity disorder; ADI-R, autism diagnosis interview-revised; ADOS, autism diagnosis observation scale; CARS, child autism rating scale; Del, deletion; EEG, electroencephalography; ID, intellectual disability; PDD-NOS, pervasive developmental disorder-otherwise not specified.
a Proband has a chromosome 9p24.3 copy number gain that is inherited from mother and considered a benign variant. The variant is inherited from father who has learning disability and attention deficit disorder.
of SHANK3 initiated from promoters 1 and 2 (SHANK3a and SHANK3b) ( Figures 1A and 2B ). The intron 19 splicing mutation will disrupt most isoforms but leave SHANK3f and other short isoforms intact. Mutations in exon 21 are expected to have no effect on mRNAs lacking exon 21 or other short SHANK3 mRNAs truncated before exon 21. Similarly, deletions within exons 1-9 and exons 1-17, and translocation breakpoints within intron 8 and exon 21, will affect different isoforms predicted from the SHANK3 gene structure. In contrast, microdeletions or large cytogenetic deletions will disrupt all SHANK3 isoforms. Therefore, the molecular consequences at the RNA and protein levels for each SHANK3 mutation are almost certainly different. A determination of how different mutations and genetic variants influence the array of potential Shank3 proteins awaits the generation of isoform-specific antibodies. If each Shank3 isoform has distinct functions at the synapse, one attractive hypothesis is that isoform-specific disruption of SHANK3 will result in different phenotypic consequences. This may offer an explanation for the clinical heterogeneity in ASD caused by SHANK3 mutations. A similar principle may be applicable to ASD caused by defects in other genes. Consistent with this notion, many known ASD genes, such as neuroligins and neurexins, display a complex pattern of isoform-specific expression in brain (Boucard et al., 2005; Sü dhof, 2008) , with different isoforms having very distinct functions (Chih et al., 2006) . In the cases of neurexins, more than 1,000 isoforms have been reported (Missler and Sü dhof, 1998). Leblond et al., 2012) . SHANK2C has an alternative stop codon due to the alternative splicing of exons 19 and 20 as shown in Figure 1B .
The expression of Shank3 isoforms is cell type-specific and developmentally regulated (Lim et al., 1999; Maunakea et al., 2010) . RNA in situ hybridization in rat brain using a single probe from exon 21 encoding the proline-rich domain showed that Shank3 is widely expressed in all brain regions at a low level at birth but increases after 2 weeks of age in the striatum, hippocampus, cerebellum, and in layers 1 and 2 of the neocortex (Bö ckers et al., 2001 (Bö ckers et al., , 2004 . Similar findings were reported in mouse brain using a probe from exon 21 encoding the proline-rich domain of mouse Shank3 (Peç a et al., 2011) . Peak expression of Shank3 occurs at an important developmental stage of synaptic plasticity and experience-dependent circuit maturation (Bö ckers et al., 2004) . These studies, however, have not defined the isoform-specific expression of Shank3, and thus the expression profile for different Shank3 isoforms and regulation of isoform-specific expression remain to be elucidated. To add further complexity, SHANK3 has five CpG islands across the gene and these CpG islands display brain-specific and cell-type-specific DNA methylation ( Figure 1A ; Beri et al., 2007; Ching et al., 2005; Maunakea et al., 2010) . Both DNA methylation and histone deacetylase inhibitors have been shown to modulate the isoform specific gene expression of Shank3 in cultured neurons (Beri et al., 2007; Maunakea et al., 2010) . Thus, in addition to alternate promoter use and mRNA splicing, epigenetic mechanisms such as DNA methylation and histone acetylation regulate the expression of the Shank3 gene in an isoform-specific manner. Multiple intragenic CpG islands are also associated with SHANK1 and SHANK2 ( Figures 1B and 1C ), but the role of these CpG islands in transcriptional regulation remains to be investigated.
SHANK2 exhibits transcriptional regulation similar to SHANK3 . Specifically, SHANK2 has several isoforms driven by multiple promoters and alternative splicing of coding exons ( Figure 1B) . The longest Shank2e isoform containing all five protein domains was initially reported as an epithelia-specific isoform in rat (McWilliams et al., 2004) . However, a recent report indicates that SHANK2E is also expressed in brain tissues in humans . Several short isoforms (SHANK2A, SHANK2B, and SHANK2C) are transcribed from downstream promoters (SHANK2A, SHANK2B) or result from alternative splicing (SHANK2C) that contain distinct combinations of protein domains ( Figure 2C ). Tissue-specific alternative splicing of exons 19-20, exon 23, and an alternative stop codon in exon 22 of SHANK2C have also been identified in humans ( Figure 1B ; Leblond et al., 2012) . The alternative splicing of exons 19-20 and isoforms of SHANK2E (Y.-h.J., unpublished data), SHANK2A, and SHANK2B (Lim et al., 1999) were conserved in mice but the status of SHANK2C and other spliced exons has not been confirmed. Similar to SHANK3, the combination of different promoters and splicing is expected to produce substantial protein diversity of SHANK2 that may carry out distinct functions at synapses. Although similar complexity of transcriptional structure has been suggested for SHANK1 ( Figure 1C) , detailed transcript profiles related to alternative promoters and exons remain to be delineated (Lim et al., 1999) . Together, the available evidence indicates that the overall transcriptional structure of SHANK family genes is conserved in mice . However, the complexity of transcriptional regulation poses a significant technical challenge to adequately model human SHANK mutations in mice.
Modeling SHANKs Mutations in Mice
Mutant mice for all Shank family genes have now been produced and characterized (Figure 3) . Shank1 mutant mice with a deletion of exons 14-15 encoding the PDZ domain were first reported in 2008 (Hung et al., 2008;  Figure 3C ), and more extensive behavioral analyses were conducted subsequently (Silverman et al., 2011; Wö hr et al., 2011) . The targeted deletion of exons 14-15 is believed to produce a null allele of Shank1. Because the transcript structure has not been fully characterized, the possibility that this is not a complete Shank1 knockout cannot be ruled out. The major molecular and behavioral phenotypes of Shank1 mutant mice are summarized in Table 3 . The synaptic proteins GKAP/SAPAP and Homer are reduced in the PSD of Shank1 À/À mouse brain. Smaller dendritic spines were observed, but the ultrastructure of the PSD is unaffected at CA1 synapses of Shank1 À/À mice. Basal synaptic transmission was reduced but long-term potentiation (LTP) and long-term depression (LTD) in CA1 hippocampus were unaffected (Hung et al., 2008) . Behavioral analyses revealed subtle impairments in social interaction and communication as well as increased repetitive behaviors (Silverman et al., 2011; Wö hr et al., 2011) . Intriguingly, spatial learning and memory was enhanced in Shank1 À/À mice (Hung et al., 2008) .
Two different lines of Shank2 mutant mice have been recently reported (Schmeisser et al., 2012; Won et al., 2012) . Schmeisser et al. reported Shank2 exon 7 deletion mutant mice (Shank2 Dex7) while Won et al. described mice with both exons 6 and 7 deleted (Shank2 Dex6-7). Exons 6-7 encode the PDZ domain of Shank2. Importantly, the exon numbering is defined based on mouse Shank2a/ProSAP1a isoform cDNA (AB099695 or NM_00111373). Full-length mouse Shank2 mRNA has not been reported or deposited in a public database. Using the longest rat cDNA of Shank2 deposited in GenBank (NM_201350) as a reference, one can deduce that exons 6 and 7 in mouse Shank2a isoform correspond to exons 16 and 17 of predicted full length mouse Shank2 deduced from rat cDNA (NM_201350) ( Figure 3B ). The difference in exon numbering for SHANK2 in different organisms in other reports is likely due to the pattern of uncharacterized exons or alternative splicing Lim et al., 1999; McWilliams et al., 2004) . The deletion of exon 7 and exon 6-7 of Shank2a (exons 17 and exons 16-17 of predicted full-length Shank2) resulted in a frame shift of the Arp 2/3 complex, regulation of actin-based cytoskeleton, dendritic spine formation and remodeling, synaptic transmission and plasticity, AMPA receptor endocytosis Haeckel et al., 2008; Lu et al., 2007; Okamoto et al., 2001; Proepper et al., 2007; Qualmann et al., 2004; Soltau et al., 2002 Soltau et al., , 2004 Tu et al., 1999 
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Review open reading frame immediately after exon 7. Therefore, the molecular nature of these two targeted mutations is predicted to be very similar at protein level. Analyses of protein composition, synaptic development and function, and behaviors have revealed similarity but also significant differences between these two lines of Shank2 mutant mice (Table 3) . Below, we utilize the exon 6-7 nomenclature based on numbering from promoter 2 of Shank2a/ProSAP1a. Full-length exon numbering is depicted in Figure 3B . Biochemically, protein composition at synapses was altered in both Shank2 Dex7 and Dex6-7 mice but with slight differences. In Shank2 Dex7 À/À mice, GluN1 and GluN2B NMDAtype glutamate receptors in hippocampus and GluN1, GluN2A, and GluA1 in striatum are increased (Schmeisser et al., 2012) . Interestingly, Shank3 was upregulated in striatum of Shank2 Dex7 À/À mice. In Shank2 Dex 6-7 À/À mice, reduction of phosphorylated CaMKIIa/b (T286), ERK1/2, p38, and GluA1 (S831/S845) was observed in hippocampus (Won et al., 2012 Figure 3A ). The mutations in these mice include deletions of exons 4-9 by two groups with slightly different design (Dex4-9
Buxbaum(B) [Bozdagi et al., 2010] and Dex4-9 Jiang (J) Figure 3A ). Isoform-specific disruption of Shank3 was evident in Dex4-7, Dex4-9 J , Dex11, and Dex13-16 mice (Peç a et al., 2011; Schmeisser et al., 2012; Wang et al., 2011) . The Dex4-9 J deletion disrupted mRNA transcripts from promoters 1 and 2 (Shank3a and Shank3b) but not Shank3c-f as confirmed by isoform-specific RT-PCR analysis . One unexpected finding from RNA expression analysis of Dex4-9 J mice was the presence of an mRNA splice isoform from exon 2 to exon 10, in addition to the expected splicing isoform from exon 3 to exon 10 due to the deletion of exons 4-9 . Intriguingly, this cryptic splicing from exon 2 to 10 occurred only in brain but not in kidney of Dex4-9 JÀ/À mice. The mRNAs with joining of exons 2-10 and exons 3-10 were stable and were predicted to result in a frame shift in protein sequence shortly after exon 10. Whether the same cryptic splicing occurs in the Dex4-9 B mutant mice has not been investigated (Bozdagi et al., 2010) . Although targeted deletion may interfere with pre-mRNA splicing mechanisms, the basis for tissue specificity of cryptic splicing is unknown. This observation adds to the complexity of predicting the molecular consequence of different mutations in Shank3 mutant mice, and perhaps in human SHANK3 mutations, and suggests that lines of Shank3 mutant mice are shown. The transcripts from promoters upstream of deleted exons are predicted to be truncated or disrupted (red arrows) and the transcripts from promoter downstream of deleted exons are predicted to be intact in each mutant line of mice (black arrows). Bottom panels depict predicted isoform-specific expression of Shank3 mRNA and proteins in Shank3 mutant mice. The ''À'' indicates that the isoform is disrupted and ''+'' indicates the isoform remains intact. The full complement of Shank3 mRNA and protein isoforms that derive from combinations of alternative promoters and mRNA splicing remains unknown. Therefore, the pattern of isoform-specific expression and disruption by specific mutations is likely more complex than indicated.
(B) Schematic of mouse Shank2 gene structure and mouse mutations of Shank2. The sequence of Shank2 full-length mRNA is not available and the intron-exon structure is deduced from a longest rat Shank2 cDNA deposited in GenBank (NM_201350). Exons in red are alternatively spliced. The human isoforms of SHANK2E, SHANK2A, and SHANK2B are conserved in mice (Shank2e, Shank2a, and Shank2b), but the status of SHANK2C is unknown. The Dex7 and Dex6-7 mutations (exon numbering based on the sequences of Shank2a/ProSAP1A cDNAs NM_001113373 or AB099695) described in the Shank2 mutant mice are shown (Schmeisser et al., 2012; Won et al., 2012) . Exons 6 and 7 in Shank2a are deduced to correspond to exons 16 and 17 in the full length Shank2 gene structure diagram. The Shank2a a Dex7 or Dex6-7 is predicted to cause truncation of all transcripts of Shank2 from the promoters upstream of exons 6-7 (red arrows).
(C) Schematic of mouse Shank1 gene structure and mouse mutation of Shank1. The deletion of exons 14-15 is predicted to disrupt all isoforms of Shank1 (Shank1a and 1b in red arrows) (Hung et al., 2008) . In (A)-(C), genomic distance and exons are not drawn to scale. Increased anxiety-like behavior. Impaired nesting behavior.
Increased anxiety-like behaviors.
AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; LTP, long-term potentiation; LTD, long-term depression; mEPSC, miniature excitatory postsynaptic current; mIPSC, miniature inhibitory postsynaptic current; NMDA, N-methyl-D-aspartate; I/O, input/output; mGluR5, metabotropic glutamate receptor 5; USV, ultrasonic vocalization.
otherwise similar mutations such as Dex4-9 B , Dex4-9 J , and Dex4-7 may have different molecular consequences for Shank3 at the mRNA and protein level. The Dex11 mutation (Schmeisser et al., 2012 ) is predicted to disrupt promoters 1 to 3 for Shank3a-c but not promoters 4 to 6 for Shank3d-f, while the Dex13-16 mutation (Peç a et al., 2011 ) is predicted to disrupt transcripts from promoters 1 to 4 (Shank3a-d) but not from promoters 5 to 6 (Shank3e-f) ( Figure 3A ; Peç a et al., 2011), although this prediction requires molecular confirmation. The effect on alternative splicing of these targeted mutations has not been determined and, as of yet, the full complement of Shank3 mRNA transcripts and splice variants is not known and awaits characterization at the mRNA and protein level. Beyond the mouse models, it will be important to know the isoform expression of SHANK3 protein in patients carrying various mutations if postmortem brain tissue becomes available.
Phenotypic analyses at the biochemical, synaptic, and behavioral levels were performed extensively on either heterozygotes or homozygotes at different ages for Shank3 Dex4-7, Dex4-9 J , Dex4-9 B , and Dex13-16, but to a lesser degree in Dex11 mutant mice (Bozdagi et al., 2010; Peç a et al., 2011; Schmeisser et al., 2012; Wang et al., 2011; Yang et al., 2012) . The methods and techniques used in these analyses were similar but not identical. Different brain regions including hippocampus, striatum, and neocortex were analyzed in different lines of mutant mice. Overall, the data obtained from these studies support a general conclusion that synaptic function is impaired and social behaviors are abnormal in mice with Shank3 mutations. In the following sections, we compare and contrast phenotypes observed with the various Shank3 mutant mice which are also summarized in Table 4 .
Synaptic Proteins in Shank3-Deficient Mouse Brain PSD proteins were altered in different brain regions of all Shank3 mutant mice but to varying degrees in the hippocampus of Dex4-9 B+/À , Dex4-9 JÀ/À , and Dex11
À/À
; the striatum of Dex11 À/À and Dex13-16 À/À ; and neocortex of Dex11 À/À mice.
Homer1b/c and GKAP1/SAPAP1 were reduced in the PSD fraction but not in the cytosolic fraction of Dex4-9 JÀ/À hippocampus . Homer1, GKAP/SAPAP, and PSD-93 were reduced in PSD fractions isolated from the striatum of Dex13-16 À/À mice (Peç a et al., 2011) but GKAP/SAPAP was not reduced in striatum of Dex11 À/À mice (Schmeisser et al., 2012) . Interestingly, Shank2 was increased in the synaptosomal fraction of Dex11 À/À striatum, while Shank3 was found to be increased in Shank2 Dex7 À/À mutant mice (Schmeisser et al., 2012) . This compensatory mechanism may contribute to the reciprocal changes in Shank2 Dex7 À/À and Shank3 Dex11 À/À mice. It will be interesting to examine whether the same phenomena occurs in other Shank3 mutant mice. Many of these proteins were either not altered in the neocortex or not examined in neocortex in these mutant mice. The corresponding changes of Homer1 and Shank3 in several mouse lines and several brain regions are consistent with the known multimeric network formed between these two proteins (Hayashi et al., 2009; Tu et al., 1999) . Mutations of Shank3 altered the levels of synaptic glutamate receptors. The AMPA receptor subunit GluA1 was reduced in hippocampal neurons examined in culture and hippocampal tissues from Dex4-9 JÀ/À and Dex4-9 B+/À mice (Bozdagi et al., 2010) , and GluA2 was reduced in the striatum of Dex13-16 À/À mice (Peç a et al., 2011 ). In the case of NMDA receptors, GluN2A subunit was reduced in the hippocampus of Dex4-9 JÀ/À mice . Both GluN2A and GluN2B subunits were reduced in the striatum of Dex13-16 À/À mice (Peç a et al., 2011), but they were unchanged in the stratum of Dex11 À/À mice (Schmeisser et al., 2012) . In contrast, GluN2B
was increased in synaptosomal fractions from Dex11 À/À hippocampus (Schmeisser et al., 2012) . In nearly all mouse lines and brain areas examined, changes in the level of these synaptic proteins and receptors was relatively modest, and many other known Shank3 interacting proteins listed in Table 2 were not altered or not examined in mutant mice. The specific patterns of altered synaptic proteins varied among different mutant mice lines with similar mutations. Such variation may be due to isoform-specific effects of different mutations. However, a direct comparison, ideally by running the same experiments head-tohead for each line of mutant mice with matched genotypes and age, will be important for a quantitative comparison of the effects of Shank3 mutations on synaptic protein composition at synapses of different brain regions.
Synaptic Structure in Shank3 Mutant Mice
The ultrastructure of glutamatergic synapses was examined by electron microscopy (EM) in all mutant mice except the Dex4-9 B+/À line. Decreased PSD thickness and length were observed at corticostriatal synapses in Dex13-16 À/À mice (Peç a et al., 2011), but not at hippocampal CA1 synapses in ex4-9 JÀ/À mice or Dex11 À/À mice (Schmeisser et al., 2012) . Dendritic branching and spine area were increased in medium spiny neurons (MSNs) of the striatum of Dex13-16 À/À mice (Peç a et al., 2011), but not examined in striatum of mice carrying other Shank3 mutations (Peç a et al., 2011; Schmeisser et al., 2012; Wang et al., 2011) . Spine length was increased in CA1 hippocampus of Dex4-9 JÀ/À mice , and spine density was decreased in the striatum and CA1 hippocampus of Dex13-16 À/À and Dex4-9 JÀ/À mice, respectively. The reduction of spine density visualized by Golgi impregnation was developmental stage-specific in Dex4-9 JÀ/À mice, with significant spine loss observed at 4 weeks but not at 10 weeks of age . Activity-induced spine growth by theta burst stimulation in cultured brain slices was attenuated at CA1 synapses of Dex4-9 B+/À mice (Bozdagi et al., 2010) .
The totality of ultrastructural and morphological analysis in Shank3 mutant mice indicates complex regulation of glutamatergic synapse size, shape, and structure. In general, mutation of Shank3 leads to loss of spines, a reduction in spine volume, and decreased PSD thickness in the adult. These effects, together with spine elongation, suggests a phenotype of reduced or delayed synapse maturation that is reminiscent of the phenotypes observed in mouse models of fragile X syndrome (Comery et al., 1997; Irwin et al., 2001) , Rett syndrome (Armstrong, 2005; Belichenko et al., 2009; Chao et al., 2007) , and Angelman syndrome (Dindot et al., 2008; Sato and Stryker, 2010; Yashiro et al., 2009 ). Notably, synapse structure (Bozdagi et al., 2010) and Dex4-9 BÀ/À (Yang et al., 2012) , but not in Dex4-9 JÀ/À or Dex13- Peç a et al., 2011) , and was not examined in Dex11 À/À mice (Schmeisser et al., 2012) . The explanation for the difference between Dex4-9 B (Bozdagi et al., 2010; Yang et al., 2012) and Dex4-9 J is not immediately clear. One possibility is that these mutations induce different cryptic splicing as described above in Dex4-9 JÀ/À mice . Another possibility is that heterozygous mutations may produce a dominant gain-of-function phenotype. In addition, mouse genetic background, animal age, and specific protocols used for the studies may contribute to the variability. In striatum, the frequency of mEPSCs and amplitude of population spikes were significantly decreased in Dex13-16 À/À mice, but only mildly affected in Dex4-7 À/À mice (Peç a et al., 2011) .
Presynaptic responses measured by paired-pulse ratio and input/output curves were not altered at corticostriatal synapses in Dex13-16 À/À or Dex4-7 À/À mice (Peç a et al., 2011) . The different degree of synaptic transmission defects in mice with specific Shank3 mutations supports the notion of an isoformspecific contribution to synaptic function. Hippocampal LTP was reduced at CA1 synapses of Dex4-9 JÀ/À and Dex4-9 B but not examined in Dex11 À/À and Dex13-16 À/À animals (Bozdagi et al., 2010; Peç a et al., 2011; Schmeisser et al., 2012; Wang et al., 2011; Yang et al., 2012) . NMDA receptor-dependent long-term depression (LTD) induced by low frequency stimulus and mGluR-dependent LTD induced by PP-LFS were not affected in CA1 hippocampus of ex4-9 B mice (Bozdagi et al., 2010; Yang et al., 2012) , suggesting an alteration in the set-point for bidirectional Hebbian synaptic plasticity (Cho and Bear, 2010) . The same analysis was not conducted in other mutant lines (Peç a et al., 2011; Wang et al., 2011) . Collectively, these data support circuit defects mediated by glutamate receptors in Shank3 mutant mice that appear to be both synapse and mutation specific. It is not yet clear whether there are common core synaptic defects in the various mutant mice, but the phenotypic heterogeneity itself appears consistent with the clinical heterogeneity of patients harboring SHANK3 mutations. Since different mutations affect different isoforms of Shank3, some of the observed phenotypes may arise from isoform-specific effects on synaptic transmission. Firm conclusions in this regard are complicated by the fact that the different No increase in self-injurious grooming.
Self-injurious grooming, causing skin lesions.
Learning and memory Shank3 isoforms are probably expressed in various Shank3 mutant mice, which were analyzed at different ages using slightly different protocols. Moreover, acute knockdown of Shank3 in cultured neurons decreases mGluR-dependent plasticity (Verpelli et al., 2011) , suggesting differences in effects of Shank3 on mGluR1/5 signaling over development and pointing to the need for cautious interpretation regarding the pathogenic versus compensatory roles of synaptic and circuit phenotypes observed in Shank3 mutant mice.
Behavioral Phenotypes in Shank3 Mutant Mice
Based on the strong genetic evidence for SHANK3 defects as a cause of human ASD, Shank3 mutant mice offer an opportunity to model autism-like behaviors in rodents. Extensive behavioral analyses were performed in Shank3 Dex4-9 B(+/À,À/À) (Bozdagi et al., 2010; Yang et al., 2012) , Dex4-9 JÀ/À , Dex4-7 À/À , and Dex13-16 À/À (Peç a et al., 2011) mutant mice at different ages, on different genetic backgrounds, and using different protocols. The most notable and consistent observation was reduced social interaction and affiliation behaviors using different testing methods (Bozdagi et al., 2010; Peç a et al., 2011; Wang et al., 2011; Yang et al., 2012) . Variable performances were noted in different cohorts of De4-9 BÀ/À mice (Yang et al., 2012) . Repetitive behaviors measured by increased self-grooming in the home cage and behavioral inflexibility in the reverse Morris water maze were observed in Dex4-9 JÀ/À and Dex4-9 BÀ/À mice (Bozdagi et al., 2010; Yang et al., 2012) but were not apparent in Dex4-7 À/À mice (Peç a et al., 2011) . A more marked increase in self-grooming and self-injurious behaviors was observed in Dex11 À/À and Dex13-16 À/À mice (Peç a et al., 2011; Schmeisser et al., 2012) .
Different severity of similar behaviors with different mutations may reflect Shank3 isoform-specific contributions to specific behaviors. The number, frequency, and duration of ultrasonic vocalizations were altered in a sex-specific manner in Dex4-9 JÀ/À mice . Reduced ultrasonic vocalizations adult were also reported in Dex4-9 B (Bozdagi et al., 2010; Yang et al., 2012) . The interpretation and predictive value of aberrant ultrasonic vocalizations in mice relative to communication behaviors in human ASD remains the subject of investigation (Holy and Guo, 2005; Scattoni et al., 2009) . Despite the consistent intellectual disability reported in patients with multiple types of SHANK3 mutations, Shank3 mutant mice differed significantly in performance of learning and memory tasks. Impaired performance in the Morris water maze task was seen in Dex4-9 JÀ/À mice but not in Dex13-16 À/À (Peç a et al., 2011) and Dex4-9 BÀ/À animals (Yang et al., 2012) . Short-term and long-term memory in a social transmission test were impaired in Dex4-9 JÀ/À mice . Prepulse inhibition (PPI) was not affected in Dex4-9 JÀ/À and Dex4-9 BÀ/À (Yang et al., 2012 ) mice but has not been examined in other mice. Deciphering the relationship between phenotypic diversity and the molecular diversity of Shank3 mutations remains a significant challenge. It is tempting to speculate that the phenotypic diversity in Shank3 mutant mice reflects the clinical heterogeneity in patients with SHANK3 defects. In a strict sense, none of these Shank3 mouse mutations are equivalent to SHANK3 mutations found in human ASD patients. The Dex4-9 (Bozdagi et al., 2010; Wang et al., 2011) and Dex4-7 mutations in mouse (Peç a et al., 2011) are closest to patients with intragenic exon 1-9 deletion and splice mutation of intron 5 in SHANK3 (Bonaglia et al., 2011; Hamdan et al., 2011;  Table 1 ). Mutations in the SH3 and PDZ domains are missense and splicing mutations in humans (Boccuto et al., 2013; Waga et al., 2011) , but mouse mutation of Dex11 and Dex13-16 are exon deletion and frame shift mutations (Peç a et al., 2011; Schmeisser et al., 2012) .
Since each mutation has a different impact on Shank3 isoform expression, a simple hypothesis is that the diversity of phenotypes in Shank3 mutant mice reflects the molecular diversity of Shank3. However, analysis of heterozygotes versus homozygotes, different measurements in different brain regions, as well as different genetic backgrounds could all contribute to phenotypic heterogeneity. Regarding genetic background, different strains used included Bruce4 C57BL/6 (D4-9 B ) (Bozdagi et al., 2010; Yang et al., 2012) , mixed 129SvEv and C57BL/6J backcrossed to C57BL/6J F7 generations (D4-9 J ) , and mixed 129SvR1 and C57BL/6 background (Dex4-7, Dex11, and Dex13-16) (Peç a et al., 2011; Schmeisser et al., 2012 ; Table 4 ). A naturally occurring Disc1 (Disrupted in schizophrenia) mutation in the 129 strain of ES cells (Clapcote et al., 2007; Clapcote and Roder, 2006) was segregated from the Dex4-9 JÀ/À deletion but was not reported in other Shank3 mutant mice using mouse 129 ES cells (Peç a et al., 2011; Schmeisser et al., 2012) . Synaptic dysfunction and abnormal behaviors have been documented in mice harboring Disc1 mutations (Clapcote et al., 2007; Kim et al., 2009) , and this may present a confounding factor for phenotypic analysis.
Translation of Shank Mutant Mice to Human ASD It is a big leap from mouse behavioral phenotypes to human clinical presentations of neurobehavioral disorders like ASD (Bu can and Abel, 2002; Moy et al., 2006; Silverman et al., 2010) . In human patients, ASD is a behavioral diagnosis with considerable clinical heterogeneity. There is currently no reliable biomarker, pathology, anatomical finding, or functional neuroimaging change that can be considered pathognomonic or predictive for ASD (Anagnostou and Taylor, 2011; Bauman and Kemper, 2005; Courchesne et al., 2007; Lord et al., 2000a) . Remarkably little is known about the neurological basis of ASD, and many brain regions and circuits have been implicated in ASD (Amaral et al., 2008; Anagnostou and Taylor, 2011; Bauman and Kemper, 2005; Courchesne et al., 2007) . Several competing hypotheses have been proposed to account for core deficits and ancillary symptomatic domains in ASD, but none have been widely accepted (Belmonte et al., 2004; Courchesne et al., 2007; Geschwind and Levitt, 2007; Rubenstein, 2010; Zoghbi, 2003) . Because of the molecular and clinical heterogeneity documented in ASD, the challenge of interpreting any human data from heterogeneous patient populations is obvious. In mouse behavioral studies, testing paradigms for learning and memory have been widely accepted (Crawley, 2008; Crawley and Paylor, 1997; Morris, 1981) . However, to date none of the various social and communication behaviors have been validated as robustly translatable from rodents to humans (Silverman et al., 2010) . This may be due to the high degree of specialization and diverse strategies for ethologically relevant social behaviors in mammals, particularly primates (Bu can and Abel, 2002; Flint and Mott, 2008; Kas et al., 2007) . Although the triad of impaired social interaction, language/communication, and stereotypical behaviors is recognized as core to ASD, the clinical presentation of these impairments is highly varied in humans. In fact, there are few clinical tools available to evaluate behavioral features quantitatively in humans that could guide more basic neurobiological studies in model systems (Lord et al., 1994 (Lord et al., , 2000b (Lord et al., , 2001 . A burning issue in the field is the extent to which common pathophysiology underlies ASD. Analyses of the Shank mutant mice indicate that subtle differences in mutations within a given ASD risk gene can produce overlapping but non-identical cellular, synaptic, and behavioral phenotypes. One approach for the future will be to tailor specific Shank mutations in the mouse to correspond precisely to human mutations where patients have undergone extensive clinical evaluation. Another important element for translating observations from Shank3 mutant mice will be to couple in vivo physiology and imaging in the mouse to functional neuroimaging in human patients to help identify conserved circuit phenotypes. Perhaps most significantly, the successful development of pharmacological therapies for core clinical features of ASD would open the door to more comprehensive data-driven validation of mouse models to better enable forward translation.
Future Directions
Numerous questions have emerged from the analysis of SHANK defects in human ASD patients and Shank mutant mice. In human patients, natural history studies of genotype and phenotype in patients with various SHANK mutations are critical. A detailed description and comparison of clinical features in patients with mutations in different SHANK genes will provide guidance for modeling human disease in animal models. Because of the similar protein domain structure among SHANK family proteins, it will be interesting to determine whether ASD patients with analogous mutations in SHANK genes have significant overlapping clinical features or whether different SHANK family members influence distinct phenotypes. At the molecular level, it will be important to know the full complement of SHANK1, SHANK2, and SHANK3 isoforms and how various ASD-linked mutations, particularly point mutations or intragenic deletions, alter SHANK2 and SHANK3 isoform expression in humans. To date, most of the expression and subcellular localization data for Shank3 have used a single RNA probe and single antibody which may fail to detect differences among Shank3 isoforms.
There is a critical need to directly compare the different Shank2 and Shank3 mutant mice head to head for cellular, synaptic, circuit, and behavioral phenotypes. Such direct comparisons will allow for more definitive identification of common synaptic defects, circuit endophenotypes, and behaviors. Can mutations in Shank2 and Shank3 open the door to a molecular pathway that provides novel therapeutic targets? Study of Shank2 Dex6-7 mice has offered a promising start (Won et al., 2012) . For example, it will be important to examine whether NMDA receptor agonists and mGluR5 positive allosteric modulators reverse phenotypes in Shank2 Dex7 À/À mice (Schmeisser et al., 2012) or in other Shank mutant mice. Perhaps more importantly, the diverse and often noncongruent phenotypes in various Shank mutant mice highlight the fact that most of the current mouse models do not carry the human mutations. Specific mutations are likely to produce specific phenotypes in patients and hence must be modeled accordingly in mice for the mutant mice to have full translational potential. Much remains to be learned, but it is tempting to consider SHANK3 ''restoration'' in a loose sense as a therapeutic strategy for Phelan-McDermid syndrome, and perhaps more broadly in ASD. Yet, anthropomorphizing rodent behavior in the hope of analogizing with symptomatic improvement in neuropsychiatric disease is fraught with cautionary tales. Interventions that improve cognitive performance, behaviors, or neuropathology in rodents have frequently not led to accelerated therapeutic development, most notably in Alzheimer's disease where reports abound of cured mouse models despite repeated clinical failures (Cissé et al., 2011; Gandy and DeKosky, 2013; Malenka and Malinow, 2011; Vaillend et al., 2002) . Ultimately, the value of Shank mutant mice will depend critically on the ability to use human patients to validate their predictive utility. Recently, whole genome sequencing technology has successfully identified a list of candidate genes in ASD (Bi et al., 2012; Chahrour et al., 2012; Iossifov et al., 2012; Neale et al., 2012; O'Roak et al., 2011; Sanders et al., 2012) , and this list will likely expand in the future. Because of the rarity of sequence variants across the population, it has been challenge to establish a causal role for specific variants in human disease. Functional studies are thus a critical component to determine the pathogenicity of specific genetic variants. The lesson learned from modeling SHANK mutations in mice will almost certainly be valuable to modeling other ASD candidate genes in the future.
